SynthesisFrontiers in transplantation2026
Cancer-related mortality among solid organ transplant recipients: systematic review and meta-analysis.
Synthesis in Frontiers in transplantation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Organ transplantation is associated with an increased risk of cancer-related mortality; however, estimates from international cohorts vary widely. The aim of this systematic review and meta-analysis is to quantify this risk. Methods: We searched MEDLINE and OVID Embase and the Cochrane Central Register of Controlled Trials (CENTRAL) for population-based cohort studies reporting cancer-related mortality in adult solid organ transplant recipients up to 2nd October 2024. Meta-analysis was conducted using a restricted maximum likelihood random-effects model. Risk of bias was assessed using the Newcastle-Ottawa Scale. Results: Seventeen registry-based studies and multicentre cohort studies met inclusion criteria. The pooled standardised mortality ratio for cancer mortality was 2.21 (95% CI: 1.82-2.68). Meta-regression showed higher mortality after heart [mortality rate ratio (MRR) 2.08, 95% CI: 1.28-3.41] and lung (MRR: 1.83, 95% CI: 1.09-3.06; Conclusion: This meta-analysis demonstrates that solid organ transplantation is associated with an increased in overall cancer-related mortality compared with the general population, with variation by organ type and cancer site. Prostate cancer showed no excess mortality risk, supporting current guidance against additional screening. In contrast, mortality from non-Hodgkin's lymphoma was increased fivefold, consistent with the established link between immunosuppression and post-transplant lymphoproliferative disease. Notably, geographic variation was observed, with lower mortality in East Asia, likely reflecting differences lifestyle risk factors and health care structures. However significant between study heterogeneity exists, underscoring the need for tailored prevention strategies, rather than relying on aggregated global estimates in this high-risk population. Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD42024617474, identifier CRD42024617474.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.